移植后较高的阿巴西普暴露降低急性GVHD风险且不增加不良事件
该研究基于ABA2研究对静脉阿巴西普进行群体药代动力学分析,评估暴露与移植结局的关系。第1剂谷浓度≥39 μg/mL与2-4级急性GVHD风险有利相关(HR 0.35,95%CI 0.19-0.65,P<.001),且未发现与复发、巨细胞病毒或EB病毒血症等安全性指标显著相关。
要点
- 第1剂谷浓度≥39 μg/mL与2-4级急性GVHD风险有利相关(HR 0.35,95%CI 0.19-0.65,P<.001)。
- 第1剂谷浓度<39 μg/mL时2-4级急性GVHD风险与安慰剂无法区分(P=.37)。
- 第1剂谷浓度与复发、巨细胞病毒或EB病毒血症等安全性指标无显著关联。
核心结论
- 较高的阿巴西普第1剂谷浓度(≥39 μg/mL)与有利的2-4级急性GVHD风险相关,且未观察到暴露-毒性关系。
研究设计与样本
- 基于ABA2研究,对静脉阿巴西普进行群体药代动力学分析,采用非线性混合效应模型,并评估暴露与关键移植结局的关联。
- 通过递归划分和分类树分析确定第1剂谷浓度的最优阈值。
主要发现
- 阿巴西普药代动力学特征为二室模型伴一级消除。
- 第1剂谷浓度≥39 μg/mL(约60%的ABA2患者达到)与2-4级急性GVHD风险有利相关(HR 0.35,95%CI 0.19-0.65,P<.001)。
- 第1剂谷浓度<39 μg/mL时2-4级急性GVHD风险与安慰剂无法区分(P=.37)。
- 第1剂谷浓度与关键安全性指标(包括复发、巨细胞病毒或EB病毒血症)无显著关联。
关键数值与推荐
- ABA2给药方案基于既往工作,目标稳态阿巴西普谷浓度为10 μg/mL。
- 第1剂谷浓度≥39 μg/mL与2-4级急性GVHD风险有利相关(HR 0.35,95%CI 0.19-0.65,P<.001)。
- 第1剂谷浓度<39 μg/mL时2-4级急性GVHD风险与安慰剂无法区分(P=.37)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the ABA2 study, the T-cell costimulation blockade agent, abatacept, was safe and effective in preventing acute graft-versus-host disease (aGVHD) after unrelated-donor hematopoietic cell transplant (HCT), leading to US Food and Drug Administration approval. Here, we performed a determination of abatacept pharmacokinetics (PK), which enabled an examination of how abatacept exposure-response relationships affected clinical outcomes. We performed a population PK analysis of IV abatacept using nonlinear mixed-effect modeling and assessed the association between abatacept exposure and key transplant outcomes. We tested the association between the trough after dose 1 (Ctrough_1) and grade (GR) 2 or 4 aGVHD (GR2-4 aGVHD) through day +100. An optimal Ctrough_1 threshold was identified via recursive partitioning and classification tree analysis. This demonstrated that abatacept PK was characterized by a 2-compartment model with first-order elimination. The ABA2 dosing regimen was based on previous work targeting a steady-state abatacept trough of 10 μg/mL. However, a higher Ctrough_1 (≥39 μg/mL, attained in ∼60% of patients on ABA2) was associated with a favorable GR2-4 aGVHD risk (hazard ratio, 0.35; 95% confidence interval, 0.19-0.65; P < .001), with a Ctrough_1 <39 μg/mL associated with GR2-4 aGVHD risk indistinguishable from placebo (P = .37). Importantly, no significant association was found between Ctrough_1 and key safety indicators, including relapse, and cytomegalovirus or Epstein-Barr virus viremia. These data demonstrate that a higher abatacept Ctrough_1 (≥39 μg/mL) was associated with a favorable GR2-4 aGVHD risk, without any observed exposure-toxicity relationships. This trial was registered at www.clinicaltrials.gov as #NCT01743131.
引用
- Takahashi T, Al-Kofahi M, Jaber M, et al. Higher abatacept exposure after transplant decreases acute GVHD risk without increasing adverse events. Blood. 2023. PMID: 37319437. doi:10.1182/blood.2023020035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。